I undersøgelsen af CML i accelereret fase viste 50 (42%) af de 119 patienter hæmatologisk respons efter at have fået Tasigna i gennemsnitligt 202 dage (ca. syv måneder).
In the study of accelerated phase CML, 50 (42%) of the 119 patients had a haematological response, after having received Tasigna for an average of 202 days (around seven months).